Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Natus Medical Incorporated (NASDAQ: NTUS) to an affiliate of ArchiMed for $33.50 in cash per share is fair to Natus Medical shareholders.

Halper Sadeh encourages Natus Medical shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Natus Medical and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Natus Medical shareholders; (2) determine whether ArchiMed is underpaying for Natus Medical; and (3) disclose all material information necessary for Natus Medical shareholders to adequately assess and value the merger consideration. On behalf of Natus Medical shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Natus Medical shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.